Aflac Inc.
AFLBusiness Overview
ticker: AFL step: 01 generated: 2026-05-12 source: quick-research
Aflac Incorporated (AFL) — Business Overview
Business Description
Aflac is the #1 supplemental insurance company in the United States and a leading supplemental health/life insurer in Japan. Founded 1955 in Columbus, Georgia. Pioneered cancer insurance in 1958. Two operating segments: Aflac Japan (~70% revenue, focus on cancer + medical insurance) and Aflac U.S. (supplemental health products including accident, disability, dental, vision, hospital indemnity). Branding hallmark: "Aflac duck" mascot.
Revenue Model
~$17.2B FY2025 revenue (down 9.3% from $18.9B in 2024) — declined due to net investment losses. Premium revenue (net earned premiums) + net investment income. Predominantly Japan: Aflac Japan generates ~70% of premium income. Lump-sum benefits paid directly to policyholders (not providers) — distinctive market positioning. Highly profitable (~22% ROE).
Products & Services
- Cancer insurance — Aflac's heritage franchise (pioneered 1958)
- Medical insurance — Japan focus (long-term)
- Accident insurance — US workplace voluntary benefit
- Disability insurance — Short + long-term
- Dental + Vision — US workplace
- Hospital indemnity — US
- Long-Term Care — New hybrid LTC rider launched 2025-26
- Medical Shield — New product rollout
- Aflac Re Bermuda — Reinsurance subsidiary (Japan Post deal 2026)
Customer Base & Go-to-Market
500,000+ independent insurance agents + brokers globally. ~90,000 employer partnerships in US providing supplemental group insurance. Heritage individual + workplace voluntary. Geographic: ~70% Japan + ~30% US. Aging Japanese population + younger US workplace = different demand dynamics.
Competitive Position
#1 US supplemental insurance. Japan's largest cancer insurer. Competes with MetLife, Prudential, AIG, Sun Life, Lincoln Financial, Unum (US); Sony Life, Tokio Marine (Japan). Differentiated by: distinctive brand (Aflac duck), lump-sum payments to policyholders, dual-market scale (US + Japan), supplemental specialty rather than core medical.
Key Facts
- Founded: 1955 (Columbus, GA, by Amos brothers)
- Headquarters: Columbus, GA
- Employees: ~12,000+
- Exchange: NYSE (AFL)
- Sector / Industry: Financials / Insurance (Life & Health)
- Market Cap: ~$60B
- CEO: Daniel Amos (since 1990, founder's nephew); Chairman
- Long-tenured CEO = 35+ years
Financial Snapshot
ticker: AFL step: 04 generated: 2026-05-12 source: quick-research
Aflac Incorporated (AFL) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | YoY (25) |
|---|---|---|---|---|---|
| Total Revenue | $19.1B | $18.7B | $18.9B | $17.2B | -9.3% |
| Net Premium Income | $15.0B | $14.6B | $14.0B | $13.4B | -4% |
| Net Investment Income | $3.7B | $3.6B | $3.6B | $3.4B | -6% |
| Adjusted Net Earnings | $5.2B | $5.6B | $5.4B | $3.6B | -33% |
| Diluted EPS | $7.69 | $9.55 | $9.59 | $6.65 | -31% |
| Net Profit Margin | 28.8% | 30.0% | 28.8% | 21.2% | -760bps |
| Annualized ROE | ~14% | ~16% | ~14% | ~22% |
Note: FY25 net earnings $3.6B reflects net investment losses + increased credit loss allowances. Q4 25 diluted EPS $2.64. Q3 25 annualized adjusted ROE ex-FX = 22.1% — strong core profitability.
Cash Flow & Balance Sheet (FY2025)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$4.0B |
| Free Cash Flow | ~$3.5B |
| FCF Conversion | ~100% |
| Cash & Equivalents | ~$5.0B |
| Total Debt | ~$8.0B (59% in yen) |
| Investment Portfolio | ~$110B |
| Yen Debt Hedge | Enterprise hedging program |
Key Ratios (approximate)
- P/E: ~16x | P/B: ~1.7x
- Revenue Growth (TTM): -9.3% | Net Margin: 21.2%
- Dividend Yield: ~2.0% | Dividend Growth: 43 years
- $3.5B 2025 buybacks (~6% of market cap)
- 114.3M shares remaining authorized for repurchase
Growth Profile
Japan core earned premiums declining 1-2% (paid-up products + aging population). US supplemental growing low-single-digit. Investment income compounding as portfolio rolls forward. Margin recovery on credit loss normalization. Hybrid LTC rider + Medical Shield new product rollouts. Aflac Re Bermuda + Japan Post deal expand reinsurance optionality.
Forward Estimates
- FY 2026: Adj EPS ~$7.00-7.50; net premium income +0-1%; ROE ~15-18%
- FY 2027: Adj EPS ~$7.50-8.00 with new product traction
- $113 average analyst price target vs ~$103 = ~10% upside
- 43-year dividend growth track record + 5.2% Q1 26 dividend increase
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $AFL.